Ilofotase Alfa for Prevention of Renal Damage After Cardiac Surgery

September 4, 2026 updated by: AM-Pharma

Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ilofotase Alfa in Patients at Risk for Renal Damage Following Open Heart Surgery

The aim of this clinical trial is to evaluate the efficacy and safety of two intravenous administrations of ilofotase alfa in patients at risk for renal damage following open heart surgery.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, 2-arm parallel group design trial in patients at risk for renal damage following open heart surgery. After screening and baseline assessments, eligible patients will be randomized 1:1 to either 2 doses of 128 mg ilofotase alfa, or 2 doses of placebo control. Randomization will be stratified by baseline eGFR and type of surgery. The patient will be treated with the investigational product (ilofotase alfa or placebo) at the same day before and after the surgery (Day 1). Follow-up clinic visits will be performed daily up to Day 5 for efficacy, safety, and pharmocokinetics assessments. A safety follow-up can be performed by telephone at Day 28. At Day 61, an end of trial visit will be done at site for efficacy, safety, and anti-drug antibodies assessments.

Study Type

Interventional

Enrollment (Actual)

271

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Genk, Belgium
        • Ziekenhuis Oost Limburg
      • Ghent, Belgium
        • Universitair Ziekenhuis Gent
      • Roeselare, Belgium
        • Algemeen Ziekenhuis Delta
      • Essen, Germany
        • Universität Duisburg-Essen, Klinik für Thorax- und Kardiovaskuläre Chirurgie
      • Munich, Germany
        • Deutsches Herzzentrum Muenchen Des Freistaates Bayern Klinik An Der Technischen Universitaet Muenchen
      • Münster, Germany
        • Westfaelische Wilhelms-Universitaet Muenster
      • Tübingen, Germany
        • Universitätsklinikum für Anästhesiologie und Intensivmedizin, Universitätsklinikum Tübingen
      • Amsterdam, Netherlands
        • Academisch Medisch Centrum Amsterdam
      • Nijmegen, Netherlands
        • Stichting Radboud University Medical Center
      • Rotterdam, Netherlands
        • Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
      • Bern, Switzerland
        • Universitätsspital Bern Universitätsklinik für Herzchirurgie
      • Lausanne, Switzerland
        • Centre hospitalier universitaire vaudois (CHUV)
      • London, United Kingdom
        • Guy's and St Thomas' NHS Foundation Trust

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Age ≥18 years

  2. Planned for one of the following types of open chest cardiovascular surgery with the use of cardiopulmonary bypass pump (CPB):

    1. 1. combined valve and CABG surgery; 2. aortic valve plus aortic root and/or ascending aorta (excluding aortic arch)
    2. CABG with 3 or more distal anastomoses
  3. Screening eGFR ≥25 mL/min/1.73m2 and ≤65 mL/min/1.73m2

  4. Female patients of childbearing potential agreeing to use effective contraception within IP treatment and 14 days thereafter

    Post-menopausal females do not require contraception during the trial.

  5. Male patients agreeing to refrain from donating sperm, use a male condom when having sexual intercourse and in case their partner is of childbearing potential they must agree to use adequate and effective contraception method (see inclusion criterion 4) within IP treatment and 14 days thereafter

The five most important Exclusion Criteria:

  1. Body weight ≤55 kg
  2. Known or suspected glomerulonephritis (other than diabetic kidney disease) or other systemic vasculitis
  3. Confirmed or treated endocarditis requiring antimicrobial or antiviral treatment within 30 days prior to surgery or other current active infection requiring antimicrobial or antiviral treatment within 14 days prior to surgery
  4. Known chronic liver disorder with Child-Pugh C classification
  5. Current planned (or scheduled) surgical intervention under conditions of circulatory arrest, including planned deep hypothermic circulatory arrest

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo

After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)

Experimental: Ilofotase alfa

After dilution of the concentrate, the investigational medicinal product will be administered by intravenous infusion for 1 hour at the same day before and after the surgery (Day 1)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum Creatinine Level Ratio
Time Frame: From Baseline (Day -1/1) to Day 5

Ratio between the highest serum creatinine value post-surgery (post-surgery Day 1 and Days 2, 3, 4, and 5) and baseline serum creatinine (pre-surgery, Day -1/Day 1). The values at post-surgery Day 1 and Days 2, 3, 4, and 5 compared to the value at baseline (Day -1/Day 1) are used to calculate the serum creatinine ratio. The reported means and standard deviations are based on patient-level ratios and include observed and imputed values.

From Baseline (Day -1/1) to Day 5

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of Major Adverse Kidney Events (MAKE) 60
Time Frame: 60 days

Major adverse kidney events (MAKE) 60, defined as died up to and including Day 61, have received or are receiving new renal replacement therapy (RRT) up to and including Day 61, or have a decrease in estimated glomerular filtration rate (eGFR) ≥25% on Day 61 compared to the pre-surgery baseline eGFR reference value. With Day 1 being the day of surgery.

60 days
(Serious) Adverse Events up to Day28
Time Frame: Day1 to Day28

All AEs that occured up to and including Day 28 or patient's trial completion, whichever occurs first.

Day1 to Day28

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative AKI Severity (Area Under the Curve)
Time Frame: From Day 1 to Day 5

Area under the curve of daily AKI severity stage/grade (0-3) from Day 1 to Day 5; higher values indicate greater cumulative AKI severity

From Day 1 to Day 5
Number of Participants With KDIGO AKI
Time Frame: From Day 1 to Day 5

KDIGO AKI stage was measured daily from Day 1 to Day 5 after surgery. A participant was counted as 'participant with KDIGO AKI', if the AKI stage was at least one day >0 from Day 1 to Day 5 after surgery.

From Day 1 to Day 5
Assessment of Length of Stay in the Intensive Care Unit
Time Frame: From Baseline to Day 28

Length of stay in the intensive care unit (ICU) in days after the initial surgery

From Baseline to Day 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Pickkers, Prof, MD, PhD, Radboud University Medical Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 19, 2023

Primary Completion (Actual)

October 5, 2025

Study Completion (Actual)

December 3, 2025

Study Registration Dates

First Submitted

December 5, 2023

First Submitted That Met QC Criteria

December 5, 2023

First Posted (Actual)

December 13, 2023

Study Record Updates

Last Update Posted (Actual)

September 29, 2026

Last Update Submitted That Met QC Criteria

September 4, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • AP-recAP-CSA-RD-02-01
  • WHO Universal Trial Number (Registry Identifier: U1111-1295-0827)
  • EU Clinical Trial Number (Registry Identifier: 2023-505859-45)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.